Roche Holding AG
SIX:ROG

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:ROG
Watchlist
Price: 249.7 CHF 2.42%
Market Cap: 202.1B CHF

ROG's latest stock split occurred on May 4, 2001

The company executed a 100-for-1 stock split, meaning that for every share held, investors received 100 new shares.

The adjusted shares began trading on May 4, 2001. This was the only stock split in ROG's history.

Last Splits:
May 4, 2001
100-for-1
Pre-Split Price
N/A
Post-Split Price
107.3735
Before
After
Last Splits:
May 4, 2001
100-for-1

Roche Holding AG
Stock Splits History

ROG Stock Splits Timeline
May 4, 2001
May 4, 2001
Split 100-for-1
x100
Pre-Split Price
N/A
Post-Split Price
107.3735
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 7, 2025
BioNexus Gene Lab Corp
NASDAQ:BGLC
1-for-10
/10
0.235 2.35 USD 2.92 2.92 USD
Apr 7, 2025
Alligator Bioscience AB
STO:ATORX
1-for-1000
/1000
0.0055 5.5 SEK 5.4 5.4 SEK
Apr 7, 2025
Treasure Global Inc
NASDAQ:TGL
1-for-50
/50
0.057 2.85 USD 2.8 2.8 USD
Apr 7, 2025
S
Safe & Green Development Corp
NASDAQ:SGD
105-for-100
x1.05
1.28 1.219 USD 1.14 1.14 USD
Apr 7, 2025
G
Ge-Shen Corporation Bhd
KLSE:GESHEN
959692-for-319897
x3.0000031260062
4.35 1.45 MYR 1.37 1.37 MYR
Load More

Roche Holding AG
Glance View

Economic Moat
None
Market Cap
199.1B CHF
Industry
Pharmaceuticals

Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.

ROG Intrinsic Value
272.74 CHF
Undervaluation 8%
Intrinsic Value
Price
Back to Top